THE CHALLENGE QUESTION

How can we unite people living with psoriatic disease and their healthcare providers to achieve optimal health outcomes?

APPLY NOW*
An Amgen initiative

*Amgen exercises diligence in ensuring compliance with local law and policy. All patient organizations are strongly encouraged to consult country specific law and compliance guidance before applying as certain countries are unable to receive these types of donations and grants based on local law or policy. Your submission could be impacted by these laws at any time throughout the application process. We appreciate your understanding and support.

The UPLIFT Innovation Challenge
Amgen invites psoriasis and psoriatic arthritis-focused patient organizations from around the world to participate in the UPLIFT Innovation Challenge. Leveraging findings from the UPLIFT survey, the initiative aims to make a big impact by developing solutions to a challenge that people with psoriatic disease and their healthcare providers continue to face.
Question Mark

THE CHALLENGE QUESTION

How can we unite people living with psoriatic disease and their healthcare providers to achieve optimal health outcomes?

*Amgen exercises diligence in ensuring compliance with local law and policy. All patient organizations are strongly encouraged to consult country specific law and compliance guidance before applying as certain countries are unable to receive these types of donations and grants based on local law or policy. Your submission could be impacted by these laws at any time throughout the application process. We appreciate your understanding and support.

Process & Timeline
All submitted applications will be evaluated via established judging criteria by an external panel of experts.                         
File
July 14
Applications open
Hand
August 30
Applications close
Cup
October/November
Successful applicant announced
The Judging Panel
The global, multi-disciplinary judging panel consists of a member of the advocacy community, leading medical experts in the psoriatic disease field and an inspiring patient and advocate.
nikita-chopra
Nitika
Chopra

Founder of Chronicon and patient living with psoriasis and psoriatic arthritis

silvia
Silvia
Fernandez Barrio

President, AEFPSO/Psoriasis Association of Argentina, International Federation of Psoriasis Associations Board Member

linda
Dr. Linda
Stein Gold

Director of Dermatology Clinical Research Henry Ford Health System

william
Dr. William
Tillett

Consultant, Rheumatologist Royal National Hospital for Rheumatic Diseases

Criteria
Applications will be evaluated against the following criteria. Please download our application guidelines for further information.
1

Does the solution effectively address the challenge question?

How can we unite people living with psoriatic disease and their
healthcare providers to achieve optimal health outcomes?
2 Is the intended audience clearly described?
3 Is the potential impact on the intended audience clearly described?
4 Have quantitative and qualitative metrics been defined?
About UPLIFT
In 2020, Amgen conducted the global Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey exploring the evolution of attitudes and behaviors of physicians treating and people living with psoriasis and psoriatic arthritis.1
Computer

UPLIFT surveyed approximately 4,700 people:1

  • 473 dermatologists
  • 450 rheumatologists
  • 3,806 people living with psoriatic disease

The survey took place in eight countries:

Flag
United States
Flag
Canada
Flag
United Kingdom
Flag
France
Flag
Germany
Flag
Italy
Flag
Spain
Flag
Japan

The survey builds upon findings from the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, a first-of-its-kind study conducted by Celgene that looked in-depth at the effect of psoriasis and psoriatic arthritis on people living with these conditions and evaluated the associated unmet treatment needs.

Key Takeaways from UPLIFT1
Initial global findings from UPLIFT identified a persistent unmet need for people living with psoriasis, requiring renewed attention to address two core areas of disconnect.

Perception of Disease Severity

People living with psoriasis who had limited skin involvement viewed their disease as more severe than how it would be categorized by common severity assessment measures, such as Body Surface Area (BSA).

58%
of patients with limited BSA (≤3 palms) rated their current psoriasis symptoms as moderate or severe
60%
of patients with limited BSA and psoriasis in ≥1 special area (e.g., scalp) reported their current disease as moderate or severe
51%
of patients with limited BSA were receiving topicals or no treatment

Accessing Treatment

Despite more available treatment options, a significant proportion of people with psoriasis, regardless of disease severity, are still not receiving treatment.

Does your organization have a solution to address these issues? Apply now*

If more information is required, get in contact with us at UPLIFTInnovationChallenge@dna-comms.com.

APPLY NOW*

*Amgen exercises diligence in ensuring compliance with local law and policy. All patient organizations are strongly encouraged to consult country specific law and compliance guidance before applying as certain countries are unable to receive these types of donations and grants based on local law or policy. Your submission could be impacted by these laws at any time throughout the application process. We appreciate your understanding and support.

A special thank you to our UPLIFT Innovation Challenge partner, the International Federation of Psoriasis Associations (IFPA). To learn more about IFPA’s impactful work and available resources, please visit ifpa-pso.com.

Reference:

  1. Lebwohl M, et al. Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Presented at: Winter Clinical Dermatology Conference. January 2021.